All In Biotech

Drug Trial Radar · NCT04561245

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Nov 10, 2020

Primary completion

Oct 29, 2021

Study completion Oct 29, 2021

Sponsor

Lead sponsor
Altimmune, Inc.Industry
Sponsor type
Industry
First posted
Sep 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).

Conditions

  • Obesity
  • Nonalcoholic Steatohepatitis

Interventions

  • ALT-801Drug

    Injected subcutaneously (SC)

  • PlaceboOther

    Injected subcutaneously (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Time frame: Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42
  2. Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801Time frame: Baseline, Day 26
  3. Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801Time frame: Baseline to Day 26
  4. Change in body weightTime frame: Baseline to Week 6
  5. Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)Time frame: Baseline to Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Networks

    Herston, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.